Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer (NCT05806931)
Sequential Combined TAS-102 and Oxaliplatin Alternating With TAS-102 and Irinotecan (Sequential TASOXIRI) With Bevacizumab for Late-Line Metastatic Colorectal Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Who can join: Review the eligibility criteria below.
Location: Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
- RWJBarnabas Health Jersey City Medical Center — Jersey City, New Jersey
- RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) — Livingston, New Jersey
- RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — Somerset, New Jersey
- RWJBarnabas Health - Community Medical Center — Toms River, New Jersey
📞 Contact the Study Coordinator
Phone: (732) 253-5618
Email: howard.hochster@rutgers.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colon Cancer
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab — Fairway, Kansas
- A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors — Basking Ridge, New Jersey
- Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality — Rochester, Minnesota
- The Exercise And Colorectal Cancer Treatment Trial — Baton Rouge, Louisiana
- Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer — Atlanta, Georgia
- The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer — Gilbert, Arizona
Explore by condition: All Colon Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.